Testing MB11 versus Opdivo for advanced melanoma
Part of Cancer, Skin clinical trials.
This trial compares a new drug, MB11, to the standard treatment Opdivo for people with advanced melanoma that hasn't been treated yet. The goal is to see if MB11 works just as well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced (Stage III or IV) and cannot be removed with surgery.
- You cannot have had any previous treatment for advanced melanoma, including immunotherapy or targeted therapy.
- You must have a tumor sample available for testing.
- You must be in generally good health, as determined by standard blood tests and your doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
This trial tests a new drug, OPM-101, combined with an immunotherapy drug (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if this combination can help control the cancer.
This study tests a new way of giving a combination of two immunotherapy drugs (ipilimumab and nivolumab) for advanced melanoma. The drugs are given either into a vein or into the skin, to see if the skin injection works as well and causes fewer side effects.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Advanced (Unresectable or Metastatic) Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.